Safety and tolerability saftey
Conditions
Interventions
Patients are given CBD with dose escalation.
Treatment
CBD10
Sponsors
Prasat Neurological Institute
Department of Medical Services
Eligibility
Sex/Gender
All
Age
18 Years to 95 Years
Inclusion criteria
Inclusion criteria: 1) Stable Parkinson's disease patient with unchanged medications for at least 1 month before enrolling to the trial 2) Parkinson's disease patient who tested for memory(TMSE)not more than 1 year and the score is not less than 23 bofore enrolling to the trial 3) Parkinson's disease patient without cannabidiol usage within 1 month before enrolling to the trial 4) Parkinson's disease patient with the age of over 18 years old 5) Willing and able to give informed consent
Exclusion criteria
Exclusion criteria: 1) Parkinson's disease patient with -Psychiatric disease -dementia -cardiovascular disease -arrhythmia -liver disease or abnormal liver function test(AST orALT more than 40 U/L -epilepsy 2)Parkinson's disease patient who is pregnant or lactating 3)Parkinson's disease patient who is not willing to participate in this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and Tolerability of Cannabidiol in Parkinson’s disease patient at 6 months after end of the intervention Adverse events grading | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy of Cannabidiol in Parkinson’s disease patient 1 day after end of the intervention Unified Parkinson Disease Rating Scale Part III | — |
Countries
Thailand
Contacts
Public ContactAkravudh Viriyavejakul
Prasat Neurological Institute
Outcome results
None listed